论文部分内容阅读
目的：对甲氧基肉桂酸乙酯（ＥＭＣ）的免疫药理研究。方法：通过３Ｈ－ＴｄＲ掺入法观察该药对正常人外周血淋巴细胞及小鼠脾脏淋巴细胞转化的影响；通过小鼠同种异位心脏移植物存活时间，观察该药对移植物排斥反应的影响。结果：ＥＭＣ（３０μｇ·ｍｌ１～１００μｇ·ｍｌ１）对植物血凝素（ＰＨＡ）诱导的正常人外周血淋巴细胞转化有显著的抑制作用。体内给予ＥＭＣ（５ｍｇ·ｋｇ１×６ｄ，ｉｐ）对ＰＨＡ诱导的Ｔ淋巴细胞转化有显著的抑制作用（Ｐ＜０．０５），对脂多糖（ＬＰＳ）诱导的Ｂ淋巴细胞转化与对照组没有显著性差异。ＥＭＣ（５ｍｇ，２５ｍｇ·ｋｇ１×６ｄ，ｉｐ）未见延长小鼠异体心肌组织移植物的存活期。结论：ＥＭＣ可抑制ＰＨＡ诱导的正常人外周血及小鼠脾脏淋巴细胞转化。
Objective: To study the immunopharmacology of methoxycinnamate (EMC). Methods: 3H-TdR incorporation method was used to observe the effect of this drug on the transformation of normal human peripheral blood lymphocytes and splenic lymphocytes in mice. The survival time of allograft heart allografts in mice was observed, Impact. RESULTS: EMC (30μg · ml1 ~ 100μg · ml1) had a significant inhibitory effect on the PHA-induced transformation of normal human peripheral blood lymphocytes. In vivo, administration of EMC (5mg · kg1 × 6d, ip) significantly inhibited the PHA-induced T lymphocyte transformation (P <0.05), and inhibited the proliferation of B lymphocytes induced by lipopolysaccharide (LPS) No significant difference. EMC (5mg, 25mg · kg 1 × 6d, ip) did not extend the survival of allogeneic myocyte grafts in mice. Conclusion: EMC can inhibit PHA-induced normal human peripheral blood and mouse spleen lymphocyte transformation.